Stay updated on Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial

Sign up to get notified when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Revision: v3.4.3 added; Revision: v3.4.2 removed.
    Difference
    0.1%
    Check dated 2026-03-07T08:47:01.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    No Change Detected
  4. Check
    28 days ago
    Change Detected
    Summary
    Revision updated from v3.4.1 to v3.4.2; no study content or eligibility details were altered. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-13T17:35:35.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    Revision: v3.4.0 updated to v3.4.1 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-06T11:27:27.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    Glossary controls (Show glossary / Hide glossary) were added, and data fields were updated or renamed (Results First Posted, Last Update Posted, Last Update Submitted that Met QC Criteria). The labels 'Results First Posted (Estimated)' and 'No FEAR Act data' were removed, and the revision updated to v3.4.0.
    Difference
    0.4%
    Check dated 2026-01-23T04:31:07.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    - Revision label in the IPD Sharing Information section updated from v3.3.3 to v3.3.4.
    Difference
    0.1%
    Check dated 2026-01-16T01:27:20.000Z thumbnail image
  8. Check
    80 days ago
    Change Detected
    Summary
    Added a Locations section with Massachusetts site details and updated the revision to v3.3.3; removed the older Massachusetts Locations entry and the HHS Vulnerability Disclosure.
    Difference
    0.2%
    Check dated 2025-12-24T12:16:34.000Z thumbnail image

Stay in the know with updates to Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin + Pembrolizumab in Soft Tissue Sarcomas Clinical Trial page.